Skip to content
10-K

Annual Report

BioNexus Gene Lab Corp. BGLC

0001477932-26-002218

← back to feed
Filed
Apr 14, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Dec 31, 2025 2.42M sh
Capex FY 2025 · Dec 31, 2025 $36.97K
Capex FY 2025 · Dec 31, 2024 $226.99K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$1.84M
Operating Cash Flow restated FY 2025 · Dec 31, 2024 −$2.09M
Cash And Equivalents FY 2025 · Dec 31, 2025 $2.49M
Cash And Equivalents FY 2025 · Dec 31, 2024 $2.89M
Stockholders Equity FY 2025 · Dec 31, 2025 $8.61M
Stockholders Equity FY 2025 · Dec 31, 2024 $8.32M
Stockholders Equity FY 2025 · Dec 31, 2023 $9.66M
Current Liabilities FY 2025 · Dec 31, 2025 $520.96K
Current Liabilities FY 2025 · Dec 31, 2024 $1.95M
Total Liabilities FY 2025 · Dec 31, 2025 $637.86K
Total Liabilities FY 2025 · Dec 31, 2024 $2.11M
Current Assets FY 2025 · Dec 31, 2025 $5.45M
Current Assets FY 2025 · Dec 31, 2024 $7.43M
Total Assets FY 2025 · Dec 31, 2025 $9.25M
Total Assets FY 2025 · Dec 31, 2024 $10.43M
Sga Expense FY 2025 · Dec 31, 2025 $1.54M
Sga Expense restated FY 2025 · Dec 31, 2024 $1.83M
Rd Expense FY 2025 · Dec 31, 2025 $50.67K
Rd Expense FY 2025 · Dec 31, 2024 $47.51K
Net Income FY 2025 · Dec 31, 2025 −$2.98M
Net Income FY 2025 · Dec 31, 2024 −$1.6M
Operating Income FY 2025 · Dec 31, 2025 −$2.97M
Operating Income FY 2025 · Dec 31, 2024 −$1.57M
Gross Profit FY 2025 · Dec 31, 2025 $1.09M
Gross Profit FY 2025 · Dec 31, 2024 $1.29M
Cost Of Revenue FY 2025 · Dec 31, 2025 $6.34M
Cost Of Revenue FY 2025 · Dec 31, 2024 $8.22M
Revenue FY 2025 · Dec 31, 2025 $7.42M
Revenue FY 2025 · Dec 31, 2024 $9.51M